Evidence map›Paper›PMID 26968800›Full record

Trial reportArthritis research & therapy2016

The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.

Tue Wenzel Kragstrup, Stinne Ravn Greisen, Morten Aagaard Nielsen, Christopher Rhodes, Kristian Stengaard-Pedersen, Merete Lund Hetland, Kim Hørslev-Petersen, Peter Junker, Mikkel Østergaard, Malene Hvid and 4 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Interleukin-24 in type 2 immune diseases.Frontiers in immunology · 2026
    Review
  4. Article
  5. Interleukin-24 Immunobiology and Its Roles in Inflammatory Diseases.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. IL-12/IL-23p40 identified as a downstream target of apremilast inTherapeutic advances in musculoskeletal disease · 2019
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Tue Wenzel KragstrupDepartment of Biomedicine, Aarhus University, Aarhus, Denmark. kragstrup@biomed.au.dk.
Stinne Ravn GreisenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Morten Aagaard NielsenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Christopher RhodesDepartment of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.
Kristian Stengaard-PedersenDepartment of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
Merete Lund HetlandCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet and Glostrup Hospital, Glostrup, Denmark.
Kim Hørslev-PetersenUniversity of Southern Denmark, Odense, Denmark.
Peter JunkerOdense University Hospital, Odense, Denmark.
Mikkel ØstergaardCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet and Glostrup Hospital, Glostrup, Denmark.
Malene HvidDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Thomas Vorup-JensenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
William H RobinsonDepartment of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.
Jeremy SokoloveDepartment of Immunology and Rheumatology, Stanford University, Stanford, CA, USA.
Bent DeleuranDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Aarhus University · DKAarhus University Hospital · DKStanford University · USGlostrup Hospital · DKOdense University Hospital · DKUniversity of Southern Denmark · DK

Funding

Training Program in Adult and Pediatric RheumatologyT32AR050942 · NIAMS · STANFORD UNIVERSITY · PI LEWIS, DAVID BRAM, ROBINSON, WILLIAM H · 2005 to 2025
$6.6M
NIAMS NIH HHS T32 AR050942
6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor, anti-citrullinated protein antibodies, and bone erosions. Current therapies can compromise immunity, leading to risk of infection. The interleukin-20 receptor (IL-20R) axis comprising IL-19, IL-20, and IL-24 and their shared receptors activates tissue homeostasis processes but not the immune system. Consequently, modulation of the IL-20R axis may not lead to immunosuppression, making it an interesting drug target. We evaluated the role of the IL-20R axis in RA and associations between plasma cytokine levels and clinical disease.

methodsPlasma IL-19, IL-20, and IL-24 levels were measured in early RA patients during a treat-to-target strategy by enzyme-linked immunosorbent assays. The IL-20R1 and IL-22R1 levels in paired peripheral blood mononuclear cells and synovial fluid mononuclear cells from a different cohort of RA patients were evaluated by flow cytometry and confocal microscopy. Monocytes/macrophages were stimulated with heat-aggregated human immunoglobulin immune complexes and immune complexes containing citrullinated fibrinogen, and osteoclasts were incubated with IL-19, IL-20, and IL-24.

resultsThe plasma concentrations of IL-20 and IL-24 (but not IL-19) were increased in early RA patients compared with healthy controls (both P < 0.002) and decreased after 6 months of treatment (both P < 0.0001). The expression of IL-22R1 (but not IL-20R1) was increased on monocytes from RA synovial fluid compared with monocytes from both RA and healthy control peripheral blood. The plasma concentrations of IL-20 and IL-24 were increased in rheumatoid factor and anti-citrullinated protein antibody positive compared with negative early RA patients (all P < 0.0001). Immune complexes stimulated the production of the IL-20R cytokines by monocytes/macrophages. Increased baseline plasma concentrations of IL-20 and IL-24 were associated with Sharp-van der Heijde score progression after 24 months (Spearman's rho = 0.19 and 0.26, both P < 0.05) in the early RA patients. The IL-22R1 was expressed by osteoclast precursors and in multinucleated osteoclasts. IL-20 and IL-24 increased the secretion of monocyte chemoattractant protein 1 by these cells.

conclusionsThis study suggests that IL-20 and IL-24 link RA-associated autoantibodies with radiographic progression via the IL-22R1. Modulation of this axis holds promise as feasible anti-erosive treatment modalities in seropositive RA.

Indexed as

AdalimumabAdultAntirheumatic AgentsArthritis, RheumatoidAutoantibodiesBiomarkersDisease ProgressionEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansInterleukin-24InterleukinsLeukocytes, MononuclearMaleMethotrexateAdalimumabAntirheumatic AgentsAutoantibodiesBiomarkersIL19 protein, humaninterleukin 20interleukin-20 receptorinterleukin-22 receptorInterleukin-24InterleukinsMethotrexateReceptors, InterleukinRheumatoid FactorAutoantibody(ies)Bone resorptionCytokinesMonocytes/macrophagesRheumatoid arthritis

Identifiers

PMID26968800
PMCPMC4788924
OpenAlexW2294966323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.